In Irving, Texas on May 23, 2025, Caris Life Sciences® unveiled that it has submitted a registration statement on Form S-1 to the U.S. Securities and Exchange Commission. Caris is recognized as a top patient-focused AI TechBio firm and a trailblazer in precision medicine. This move showcases the company's commitment to growth and likely signals upcoming financial activities.